Skip to content

Esperion Therapeutics ESPR Number of finance leases

Number of finance leases at other companies

AZZ logo
AZZAZZ
139+87.8%
REX American Resources logo
REX American ResourcesREX
1
Grand Canyon Education logo
Grand Canyon EducationLOPE
0
Crown Castle logo
Crown CastleCCI
$4M-42.9%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
2-66.7%
Winnebago Industries logo
Winnebago IndustriesWGO
$0-100%

Other financials

Income statement

See full
Revenue$80.1M+23.2%
Operating income-$6.6M+70.2%
Net income-$25.2M+37.7%
EPS (diluted)-$0.10+52.4%

Balance sheet

See full
Cash & equivalents$156.2M+36.2%
Total debt$155.2M+6.1%
Total equity-$307.9M+27.8%
Total assets$462.5M+42.7%

Cash flow

See full
Operating cash flow-$27.7M-22.5%
CapEx$189.0K
Free cash flow-$27.9M-23.3%

Valuation

See full
Market cap$811.73M+283%
Enterprise value$810.81M+233%
P/S1.9×+1.1×

Profitability

See full
Operating margin18.1%+12.7pp
Net margin-34.8%+8.0pp
FCF margin-30.7%

Returns & leverage

See full
Return on equity-260.8%
Debt / equity0.8×
Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept espr:NumberOfFinanceLeasesNotYetCommenced.

The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's number of finance leases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Esperion Therapeutics's number of finance leases?
Esperion Therapeutics (ESPR) reported number of finance leases of 0 in Q4 2025.
What does number of finance leases mean?
This represents the number of finance lease agreements that have been signed but for which the underlying assets have not yet been placed into service. It provides visibility into future capital expenditure commitments and the planned expansion of the company's asset base. Tracking this is useful for forecasting future depreciation and interest expenses.